OR WAIT null SECS
Click here to read the articles and download the PDF
Rod MacKenzie, today the leader of global product development at Pfizer—and latest HBA Honorable Mentor—has devoted much of his career to helping others succeed, including advancing efforts to break down gender barriers in pharma.
This Pharmaceutical CEO Leadership roundtable brings together pharma Chief Digital Officers and other leaders in the space to discuss the challenges and opportunities associated with digitizing all aspects of the pharma business.
The Healthcare Businesswomen’s Association again names Sandra Horning its WoTY—where the pharma leader’s message of purpose and partnership takes on added resonance today.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
Highlighted Videos
April 14, 2021
In this roundtable discussion, Steve Gens, Remco Munnik and James Kelleher explore the potential and the practicalities of building future processes on a single, joined-up content platform.
FDA acting commissioner Janet Woodcock announced this week that Patrizia Cavazzoni will become the director of the Center for Drug Evaluation and Research (CDER), shifting from her role as acting director since last spring.
States and institutions are enacting mandates requiring greater inclusion of women and underrepresented groups on corporate boards; what are the key questions for pharma?
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
Life sciences companies uniquely tasked with meeting continuous and complex compliance-reporting requirements.
New data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.
April 13, 2021
at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?
More capital gains and the potential strains for rest of 2021.
Looking Back at 1990-1993.
